361 related articles for article (PubMed ID: 15816500)
81. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress in therapy of CKD-MBD with vitamin D receptor activators].
Shoji T
Clin Calcium; 2012 Jul; 22(7):1073-81. PubMed ID: 22750940
[TBL] [Abstract][Full Text] [Related]
82. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
Brandenburg V; Ketteler M
Nutrients; 2022 Jul; 14(15):. PubMed ID: 35893866
[TBL] [Abstract][Full Text] [Related]
83. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
Brown AJ; Coyne DW
Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
[TBL] [Abstract][Full Text] [Related]
84. Vitamin D and vascular calcification in chronic kidney disease.
Rodriguez M; Martinez-Moreno JM; Rodríguez-Ortiz ME; Muñoz-Castañeda JR; Almaden Y
Kidney Blood Press Res; 2011; 34(4):261-8. PubMed ID: 21691129
[TBL] [Abstract][Full Text] [Related]
85. Vitamin D analogs--drug design based on proteins involved in vitamin D signal transduction.
Masuda S; Jones G
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Mar; 3(1):43-66. PubMed ID: 12570725
[TBL] [Abstract][Full Text] [Related]
86. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?
Levin A; Li YC
Kidney Int; 2005 Nov; 68(5):1973-81. PubMed ID: 16221197
[TBL] [Abstract][Full Text] [Related]
87. [Vitamin D deficiency in kidney failure. Risk factor for cardiovascular disease].
Ohman K; Larsson T; Spaak J
Lakartidningen; 2010 Nov 17-23; 107(46):2884-7. PubMed ID: 21197784
[No Abstract] [Full Text] [Related]
88. The use of 1,25-dihydroxyvitamin D3 in early renal failure.
Goodman WG; Coburn JW
Annu Rev Med; 1992; 43():227-37. PubMed ID: 1580587
[TBL] [Abstract][Full Text] [Related]
89. Vitamin D, cardiovascular disease, and survival in dialysis patients.
Moe SM
J Bone Miner Res; 2007 Dec; 22 Suppl 2():V95-9. PubMed ID: 18290731
[TBL] [Abstract][Full Text] [Related]
90. Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease.
Han T; Rong G; Quan D; Shu Y; Liang Z; She N; Liu M; Yang B; Cheng G; Lv Y; Stern L
Biomed Res Int; 2013; 2013():320560. PubMed ID: 23509710
[TBL] [Abstract][Full Text] [Related]
91. Survival benefits with vitamin D receptor activation: new insights since 2003.
Kovesdy CP
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1704-9. PubMed ID: 20507950
[TBL] [Abstract][Full Text] [Related]
92. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure.
Malluche HH; Mawad H; Koszewski NJ
Kidney Int; 2002 Aug; 62(2):367-74. PubMed ID: 12109997
[TBL] [Abstract][Full Text] [Related]
93. Survival differences between activated injectable vitamin D2 and D3 analogs.
Kalantar-Zadeh K
Kidney Int; 2007 Apr; 71(8):827; author reply 827-8. PubMed ID: 17429422
[No Abstract] [Full Text] [Related]
94. [Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease].
Cozzolino M; Olivi L; Voli E; Ciceri P; Brancaccio D
G Ital Nefrol; 2009; 26 Suppl 49():S30-5. PubMed ID: 19941276
[TBL] [Abstract][Full Text] [Related]
95. The potential for vitamin D receptor activation in cardiovascular research.
Wu-Wong JR
Expert Opin Investig Drugs; 2007 Apr; 16(4):407-11. PubMed ID: 17371189
[TBL] [Abstract][Full Text] [Related]
96. Delayed hypersensitivity in primary and secondary hyperparathyroidism. Treatment with active vitamin D.
Lind L; Wengle B; Sörensen OH; Ljunghall S
Exp Clin Endocrinol; 1990 Apr; 95(2):271-4. PubMed ID: 2365023
[TBL] [Abstract][Full Text] [Related]
97. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
[TBL] [Abstract][Full Text] [Related]
98. Lymphocyte and monocyte vitamin D receptor expression during paricalcitol or calcitriol treatments in patients with stage 5 chronic kidney disease.
Sözel H; Köksoy S; Ozdem S; Yılmaz F; Bora F; Ersoy FF
Int Urol Nephrol; 2020 Aug; 52(8):1563-1570. PubMed ID: 32405698
[TBL] [Abstract][Full Text] [Related]
99. Vitamin D therapy in cardiac hypertrophy and heart failure.
Wu-Wong JR
Curr Pharm Des; 2011; 17(18):1794-807. PubMed ID: 21631423
[TBL] [Abstract][Full Text] [Related]
100. Vitamin D receptor activators.
Mazzaferro S; Pasquali M; Conte C; Mandanici G; Muci M; Lavini R
Int J Artif Organs; 2009 Feb; 32(2):101-7. PubMed ID: 19363782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
